Validation of STA-Liatest D-Di assay for exclusion of pulmonary embolism according to the latest Clinical and Laboratory Standard Institute/Food and Drug Administration guideline. Results of a multicenter management study.

Abstract

: Combined clinical pretest probability (PTP) and D-dimer testing have great diagnostic value for pulmonary embolism exclusion. To harmonize performance levels of D-dimer assays available on the market, the Clinical and Laboratory Standard Institute (CLSI) has published a guideline, endorsed by the US Food and Drug Administration (FDA). Such guideline specifies the ideal D-dimer assay characteristic and target population. This study was conducted following the CLSI guideline to upgrade the assay-intended use and obtain FDA clearance of STA-Liatest D-Di assay for pulmonary embolism exclusion in patient with low/moderate PTP. This was an international, multicenter, prospective nonrandomized, noninterventional clinical outcome management study conducted in a standard of care setting. D-dimer assay was performed in consecutive, ambulatory outpatients suspected of pulmonary embolism, with low/moderate PTP, and without medical conditions or in clinical settings known to alter default D-dimer values regardless of the presence of thrombosis using a threshold of 0.5 μg/ml (fibrinogen equivalent units) for venous thromboembolism exclusion. Results were used to determine test performance. Of 1141 patients who underwent D-dimer testing, 1060 had valid results and completed study as planned. STA-Liatest D-Di assay performance has exceeded the CLSI/FDA guidance requirements, with a sensitivity of 97.6% (95% confidence interval: 91.7-99.7%) and a negative predictive value of 99.7% (95% confidence interval: 99.0-100%). STA-Liatest D-Di assay has an excellent performance when used in combination with a PTP score in relevant patients and has the potential to minimize the economic healthcare burden avoiding unnecessary and expensive imaging tests.

• Authors: Gilles Pernod, Haifeng Wu, Emmanuel de Maistre, John Lazarchick, Jeannine Kassis, Carlos Aguilar, Pascual M Vera, Gualtiero Palareti, Armando D'Angelo, DiET Study Group (Jeffrey Caterino, Fabienne Dutrillaux, Gary Headden, Colin Kaide, Maxime Maignan, Raphaël Marlu, Anais Richard, Cindy Tissier)
• Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (Blood Coagul Fibrinolysis) Vol. 28 Issue 3 Pg. 254-260 (Apr 2017) ISSN: 1473-5733 [Electronic] England
• PMID: 27428016 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Fibrin Fibrinogen Degradation Products
• fibrin fragment D

Topics

• Biological Assay (methods)
• Female
• Fibrin Fibrinogen Degradation Products (metabolism)
• Humans
• Male
• Middle Aged
• Prospective Studies
• Pulmonary Embolism (diagnosis)
• United States
• United States Food and Drug Administration